Welcome to our dedicated page for Trevena news (Ticker: TRVN), a resource for investors and traders seeking the latest updates and insights on Trevena stock.
Trevena Inc (NASDAQ: TRVN) is a clinical-stage biopharmaceutical pioneer developing novel therapies for central nervous system disorders and pain management through advanced GPCR targeting. This page provides investors and industry professionals with a comprehensive repository of Trevena news, including clinical trial updates, regulatory milestones, and research developments.
Access timely updates on Trevena's innovative pipeline, including OLINVYK™ (oliceridine) for acute pain and investigational candidates like TRV045 for neuropathic pain. Track progress across preclinical studies, FDA communications, and strategic partnerships that shape the company's trajectory in neuroscience therapeutics.
Key content includes earnings reports, patent filings, scientific presentations, and analyses of Trevena's biased ligand platform—a Nobel Prize-influenced approach to minimizing opioid-related side effects. All materials are curated to support informed decision-making without promotional bias.
Bookmark this page for centralized access to Trevena's latest advancements in non-opioid pain management and CNS disorder treatments. Regularly updated to reflect new developments in GPCR-focused drug discovery and clinical-stage biopharma innovation.
Trevena, Inc. (Nasdaq: TRVN) announced that its drug OLINVYK (oliceridine) has been classified as a Schedule II controlled substance by the DEA, allowing distribution starting in November. This approval marks a significant milestone for the company, as it aims to provide an alternative to IV morphine for acute pain management. With approximately 45 million patients treated annually, OLINVYK offers rapid onset and requires no dosage adjustments for renal-impaired patients. The company reported cash reserves of $112.7 million, sufficient to fund operations through 2022.
Trevena, Inc. (Nasdaq: TRVN) announced three presentations at ANESTHESIOLOGY® 2020, showcasing new analyses from the Phase 3 program of OLINVYK (oliceridine) injection. Key findings revealed significant improvements in respiratory safety and gastrointestinal tolerability compared to IV morphine. OLINVYK demonstrated a lower incidence of respiratory safety events (12.8%-13.8%) versus morphine (22.8%-23.4%). Additionally, it showed better performance regarding nausea and vomiting rates, establishing its potential as a safer alternative for managing acute pain.
Trevena, Inc. (Nasdaq: TRVN) announced three presentations at the 2020 American College of Clinical Pharmacology Annual Meeting from September 21-23, discussing TRV027 as a potential COVID-19 treatment, along with OLINVYK and TRV250 data. A live presentation on TRV027 highlighted its targeted action for ARDS and clotting issues in COVID-19 patients. OLINVYK’s benefit-risk profile compared to morphine was presented, showing improved safety. TRV250's Phase 1 study indicated it’s well-tolerated for migraine treatment.
Trevena, Inc. (Nasdaq: TRVN) announced its participation in three upcoming conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23. Key presentations will be led by senior executives including Carrie Bourdow and Bob Yoder. Investors can access the webcasts on the Company's website for further insights into Trevena's focus on CNS disorders and its product pipeline.
Trevena, Inc. (Nasdaq: TRVN) announced key publications on the respiratory safety of OLINVYK (oliceridine), demonstrating its improved profile over IV morphine. A clinical utility function analysis revealed OLINVYK offers a higher probability of analgesia with lower respiratory depression risks. In Phase 3 studies, patients receiving OLINVYK experienced fewer dosing interruptions due to respiratory safety events compared to those receiving morphine. Approved by the FDA in August 2020, OLINVYK is intended for acute pain management in adults.
Trevena, Inc. has announced the initiation of a proof-of-concept study for TRV027, a selective AT1 receptor agonist aimed at treating acute lung damage and abnormal blood clotting in COVID-19 patients. Sponsored by Imperial College London, the randomized study will enroll approximately 60 hospitalized patients, focusing on TRV027's effectiveness in reducing clotting and improving lung function. Topline data is expected in Q1 2021. TRV027 has shown prior efficacy in nonclinical studies and a low dropout rate in previous trials.
Trevena, Inc. (Nasdaq: TRVN) announced a $3 million milestone payment from its Chinese partner Nhwa following the U.S. approval of OLINVYK™ (oliceridine) injection. This payment is part of a licensing agreement where Nhwa is tasked with developing and commercializing OLINVYK in China. The company anticipates further milestone payments and a 10% royalty on net sales in the region. OLINVYK is indicated for adults requiring intravenous opioid analgesics for severe pain, though it awaits scheduling by the DEA before distribution.
On August 14, 2020, Trevena, Inc. (TRVN) announced that CEO Carrie Bourdow will participate in a fireside chat during the JMP Securities CNS Forum, scheduled for August 19-20, 2020. The chat will take place on August 20 at 12:30 p.m. Eastern Time. The discussion will focus on the company's ongoing development of novel CNS treatments, including its approved product OLINVYK™ and innovative candidates like TRV250 for migraine and TRV734 for opioid use disorder. For further details, the webcast link is provided in the press release.
Trevena, Inc. (Nasdaq: TRVN) has priced a public offering of 21,739,131 shares of its common stock at $2.30 per share, aiming to raise around $50 million before deductions. The underwriters have a 30-day option to purchase an additional 3,260,869 shares. Proceeds will primarily fund the commercialization of OLINVYK and support clinical development for pipeline assets. The offering is expected to close around August 14, 2020. Guggenheim Securities is the lead manager for this offering.
Trevena, Inc. (Nasdaq: TRVN) announced an underwritten public offering of its common stock, aiming to raise funds for its CNS disorder treatments. The offering includes a 30-day option for underwriters to purchase an additional 15% of the shares. Lead managers are Guggenheim Securities and Cantor Fitzgerald. The offering is subject to market conditions, with no guarantee on its completion or terms. Trevena has one approved product, OLINVYK™, and is developing several investigational drug candidates.
